Adar Biotech
Drug Delivery Device
Startup Mature Health Tech & Life Sciences Est. 2006
Total Raised
Undisclosed
Mature
Last Round
Undisclosed
Team
1
1-10 employees
Confidence
86/100
About
Adar Biotech develops a miniature medical device for enhancing drug delivery and a medical device for homeland security/bioterrorism applications. The company also provides products and services to the research community. Adar Biotech manufactures functional resins and recombinant proteins, and supplies customers with immunological and cell-culture services. The company specializes in the generation of monoclonal antibodies to weak and difficult antigens. The numbers and properties of the resulting hybridoma clones are superior to those obtained by traditional methods. An adjuvant, selection media, and screening technology are part of Adar's immunology licensing package. Adar Biotechhas several products that are offered for licensing. Licensing activities involve inventions, patents, and various chemical formulations.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsHealthcareLaboratoriesProvidersDefense, Safety & SecuritySecurityHomeland Security
Business Model
B2GB2B
Tags
drug-deliverydentalmanufacturinglaboratoriesmedical-devicesimmunologybiotechnologygeneticsacademiahomeland-securityantibodies
Details
Product Stage
Released
Employees
1-10
Exact Count
6
District
Center District
Founded
2006
Registrar
513805556
Crunchbase
adar-biotech
Locations
Derekh Yavne 27, Rehovot, Israel
HaHarash St 16, Ness Ziona, Israel
Links
Admin
Last Update
Aug 1, 2023
Verified by
Sharon Shapira
Missing
video or image, funding rounds, news, markets, external profiles, not claimed
Team (1)
Yinon Shlomi
Founder & CEO
Founder
Internal
Created by
Tamar Weiss (tamar.e.weiss@gmail.com)
Created
2014-07-15T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)